Coronary heart disease is the single largest cause of mortality in the UK with acute myocardial infarction (AMI) being responsible for the greatest amount of deaths. Improving perfusion to the myocardium to prevent further damage or death of the cardiac tissue is the aim of treating AMI. In the UK reperfusion is achieved either through the use of an thrombolytic agent (streptokinase, alteplase,...

OBJECTIVE To examine the frequency and determinants of re-infarction after thrombolytic treatment of ST-elevation myocardial infarction (STEMI). DESIGN Observational study of national registry. SETTING Emergency ambulance services and admitting hospitals in England and Wales. PATIENTS 35 356 patients with STEMI given thrombolytic treatment in 2005-6. MAIN OUTCOME MEASURES Re-infarction ...

The bioengineered tissue plasminogen activator tenecteplase is an important treatment modality of acute myocardial infarction recommended by international guidelines. Following introduction of originator tenecteplase (brand names Metalyse(®) and TNKase(®)), a "biosimilar" tenecteplase became available for commercial use in India under the brand name Elaxim(®) in the absence of Indian biosimilar...

in the neuroscience intensive care unit at the University of Virginia Health System in Charlottesville. properties of the fibrinolytic agent and the impact of adjuvant therapies such as antiplatelet and anticoagulant agents must also be considered. Tenecteplase is a variant of tissue plasminogen activator (t-PA) that is genetically engineered to have increased fibrin specificity, a longer half-...

The use of intravenous thrombolytic agents has revolutionised the treatment of acute myocardial infarction. However, the improvement in mortality rate achieved with these drugs is tempered by the risk of serious bleeding complications, including intracranial haemorrhage. Tenecteplase is a genetically engineered mutant tissue plasminogen activator. Haemorrhagic complications of tissue plasminoge...

INTRODUCTION Prosthetic valve thrombosis (PVT) following cardiac valve replacement in rheumatic heart disease patients is a common cause for referral to tertiary care centre. Although surgery has been described as the traditional choice of therapy, thrombolytic therapy has reported high success rates in published literature. CASE REPORT This is a case report of ten patients with left-sided PV...

INTRODUCTION Prosthetic valve thrombosis is a rare but life-threatening condition that requires careful evaluation and prompt treatment. While surgical intervention remains the gold standard, thrombolytic therapy is now emerging as a potential substitute. Various thrombolytic treatments including streptokinase, urokinase and recombinant tissue plasminogen activators have been reported with vari...

BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less ...

It may be that the landscape of stroke care is changing, as more attention being drawn to benefits intravenous (IV) tenecteplase for acute reperfusion therapy, particularly given ease administration and affordability highlighted by COVID-19 pandemic. The latest ANA Investigates podcast asks Professor Bruce Campbell important questions about body evidence surrounding tenecteplase, including whet...

BACKGROUND Approximately 70% of persons who have an out-of-hospital cardiac arrest have underlying acute myocardial infarction or pulmonary embolism. Therefore, thrombolysis during cardiopulmonary resuscitation may improve survival. METHODS In a double-blind, multicenter trial, we randomly assigned adult patients with witnessed out-of-hospital cardiac arrest to receive tenecteplase or placebo...